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Abstract
Cancer is an intricate disease that can attack different parts of the human body. In the most
common types of cancer, abnormal cells divide uncontrollably and impair body tissue. Cross
disciplinary research has long aided expansion of our knowledge and ability to approach
problems with a different perspective. Engineers and clinicians can collaborate to solve
mysteries surrounding cancer cells function and responses. Engineers have contributed to
cancer treatment, by studying new ways to diagnose and treat cancer. According to a study
by John Hopkins university [6] engineered nano-particles can induce immune reaction and
kill cancer cells. In addition, new ways of delivering cancer therapy to actuate the immune
system to kill cancerous cells were found through engineering research.
The goal behind modeling biological systems is to drive the states to a desirable outcome
using control elements in the dynamic system. In this thesis, we explore the effects of an
Intelligent Proportional Integral Derivative (iPID) controllers; using optimal and model free
control to improve the state of a cancer patient using recommended safe dosages. A nonlinear mathematical model of Ordinary Differential Equations (ODE) is used to simulate a
virtual cancer patient using realistic valued parameters. It is important to bear in mind
that the human body is complex and variable. In particular, the immune response can vary
from one patient to another. The parameters used to model the cancer have been deduced
by clinicians and engineers to represent the tumor immune interaction using mathematical
equations.
The dissertation will begin by exploring the cancer therapy’s mathematical model, the
controllability and observability to assure that the model is controllable, and explore different
control methods and compare the results.
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Chapter 1
Introduction
The objective of this thesis is to control a nonlinear set of ODEs that represents a virtual
cancer patient. Control theory has long been used in different applications such as economics,
engineering, biological systems, etc. to control outside elements to produce the best possible
outcome [36]. The aim of this thesis is to explore control techniques that cure the malignant
tumor through chemo and immunotherapy and bring the virtual patient to a healthy state.
It is worth mentioning that the nonlinear cancer model does not apply to all cancer patients
because the biology of humans is different: immune response, genetics, varying underlying
health conditions, and type of cancer. Therefore, the biological reaction will also differ. In
addition, due to the lack of information in biological processes, it is difficult to accurately
model and parameterize a paradigm that is general to all cancer patients.

1.1

Motivation

Cancer is a disease in which a cluster of cells (tumor) form and divide uncontrollably. A
tumor can be benign (non cancerous) or malignant (cancerous) [7]. Benign tumors tend to
grow slowly and do not spread or invade other body parts on the other hand, a malignant
tumor can attack healthy cells and tissues and grow rapidly from the initial place where it
formed . Early diagnosis often leads to a more effective treatment because the spread of the
cancerous cells will not have reached dangerous levels. Cancer is treated differently based on
the type of cancer and how far it has expanded. Cancer severely impacts people all over the
1

world. According to the National Cancer Institute (NCI), cancer is one of the most causes
leading to death. In 2018, there were 18.1 million new cases and 9.5 million cancer-related
deaths worldwide [1]. The number is projected to increase yearly.
In recent decades, much research toward modeling the dynamics of immune system and
cancer therapy has been conducted. As a result of modeling biological systems, using
computational tools, and applying different control methodologies researches have obtained
desirable outcomes in treating illnesses as seen for example in [19, 13, 39]. The motivation
behind the thesis is to explore control methods than can assist medical professionals in cancer
treatment scheduling. The various control methods can be analyzed in order to select the
most effective drug delivery therapy. The therapy should be balanced, meaning safe amount
of dosage for quickest possible recovery time. In the next section we present a review of
cancer modeling in recent decades, the different cancer dynamics presented, and the clinical
tests carried out to attain the system parameters.

1.2

Cancer Dynamic Model

Due to the overwhelming effect of cancer on the lives of millions of people, much research
has been devoted to treatments, therapy scheduling, and diagnosis. Modeling systems in
various fields of study has been a powerful tool, allowing researchers to better understand the
behavior of systems. In addition, it allows in identifying potential outcomes due to a change,
or making adjustments to enforce a a certain outcome. Certainly, through control theory and
simulation tools, we are able to manipulate the behavior of the system and achieve desired
results. The cancer model dynamic being investigated in this thesis is composed of states
and input variables. The states are: tumor cells, lymphocyte cells, and pharmacokinetics.
The input variables include chemo and immunotherapy injections.

1.2.1

Modeling Tumor growth

Tumors occur because of accumulated epigenetic alterations within single cells which is
the change of organisms due to change in gene expression rather the genetic code itself. That
cell then divides and expands uncontrollably. The abnormal proliferation (rapid increase
2

and expansion) of tumor cells puts a strain on the human body in the sense that, these cells
feed on nutrients and oxygen to cause the tumor to grow even larger. They compete against
the healthy cells for these resources. Once the tumor starts growing in size, the cells in the
center of tumor begin to die due to lack of resources. As a results the growth of the tumor
slows down. The necrotic (dead) cells Vascular endothelial growth factor (VEGF) is
activated. It is a protein signal that stimulates angiogenesis which is the formation of
new blood vessels by sprouting from existing blood vessels to restore oxygen; since there
is a lack of blood flow. Once the new blood vessels have formed the tumor then begins to
expand again. The process is described in figure 1.1. The Tumor cells are always the first to
arrive on the scene meaning, they deplete the resources and unlike the healthy cells they can
expand and break out to other parts of the body to continue feeding and growing to form
new tumors. This process is called metastasis, where the word malignant is derived from.
According to [5], some of the key differences between tumor and normal cells are as follows:
• The cancer cells have abnormal shapes and nucleus size.
• Cancer cells are less specialized than normal cell. When normal cells form, they mature
to be distinct and have special functions and tasks.
• Tumor cells can evade signals that tell cells to stop dividing. The process is known
as programmed cell death, or apoptosis. The body uses this function to discard
unnecessary cells.
The differences between normal and cancerous cells can be seen in figure 1.2. It is evident
that the underlying process of the tumor growth is complex. So how did researchers formulate
the mathematical model of tumor growth?

In the literature one will find a variation of mathematical formulations of tumor growth
and cancer treatments. The mathematical formulations resorted to expressing the model by
Partial (PDE) or Ordinary Differential Equations (ODE) as in [31, 19] respectively. The
model parameters may also differ based on the treatment used, for example the model used
in [39] the author presents chemo and immunotherapy as control inputs while in [20] only

3

Figure 1.1: (A) Angiogenesis is the process of the development of new blood vessels from
pre-existing vessels, which allows for tumor progression; (B) Steps in angiogenesis [42]

4

Figure 1.2: Differences between normal and cancerous cells [43]

5

a chemotherapy inhibitor is used.
The general form of Tumor growth is represented by:

x˙1 = µC · x1 , x1 (0) = x01 .

(1.1)

where x1 (t) represents the tumor cells at time t and µC is the growth rate. Most models
have expanded on equation (1.1) by incorporating proliferation rate, the affect of necrotic
cells, the therapy agent inhibitors, angiogenesis, etc.
In order to limit the carrying capacity of tumor cells other terms have been proposed in the
literature [34, 38]:

x1
), x1 (0) = x01 .
x∞
x1
x˙1 = −µC x1 ln(
), x1 (0) = x01 .
x∞
x˙1 = µC x1 (1 −

(1.2)
(1.3)

which is mainly logistic growth and Gompertizian growth as seen in equations (1.2) and
(1.3) respectively. Both consider a limited cancer carrying capacity represented by x∞ . In
the thesis we focus on the logistic growth.

1.2.2

Modeling Lymphocyte Cells

In this section we present facts pertaining to the immune system summarized from [3, 8].
A Lymphocyte is a type of immune cell that is made in the bone marrow and found in the
lymph tissues. It is a type of white blood cell that combats antigens and foreign bodies. It
is part of the adaptive immune system. There are two types of immune responses: innate
and adaptive immunity. The innate immune system is the first line of defence; soon after
the appearance of antigens or a foreign substance the nonspecific defense mechanisms is
activated within hours of an antigen’s appearance in the body. The innate immune system
reacts the same way to different antigen’s every time and it does not have immune memory
which is the reason the mechanism is referred to as nonspecific. These mechanisms include
6

physical barriers such as skin, chemicals in the blood, and immune system cells that attack
foreign cells in the body.
Adaptive immunity refers to antigen-specific immune response. The mechanism of the
adaptive immunity is far more intricate than the innate response. The adaptive immunity
combats antigens as follows:
1. The antigen must be first processed and recognized
2. The adaptive immune system sends an array of immune cells to kill the antigen. It
tries using distinct types of cells and methods to get rid of the antigen.
3. If the immune system is successful in defeating the antigen, the treatment type along
with the specific antigen type are saved to the immune memory in case of future breach
of the same antigen, the immune system will be more efficient.
In Oncology modeling, the lymphocyte cells is a good indicator of the immune system and
the healthy cells. An oversimplified expression pertaining Lymphocyte cell growth is given
in (1.4):

x˙2 = µI x2 , x2 (0) = x02 .

(1.4)

where x2 (t) represents the lymphocyte cells at time t and µI denotes the tumor stimulated
proliferation rate of the lymphocyte cells. The author in [10] proposed a model that takes
into account the effects of tumor cells on lymphocyte cell growth, as can be seen in equation
(1.5)
x˙2 = µI J (x1 , x2 ), x2 (0) = x02 .
where J (x1 , x2 ) denotes the growth rate function of Lymphocyte cells.
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(1.5)

1.2.3

Modeling Chemotherapy

Chemotherapy is a drug treatment that uses powerful chemical agents such as Alkylating,
Antimetabolites, Antitumor antibiotics, etc [4]. The different types of chemotherapy agents
differ in compound and in which phase the agent interacts with the body, but it is mainly
used to kill fast growing tumor cells. Much work has been done to examine the effects of
chemotherapy interactions, in [37] the author introduced the function M in equation (1.6):

x˙1 = µC x1 (1 −

x1
) − M(x1 , u1 ), x1 (0) = x01 .
x∞

(1.6)

The concentration at time t of the chemotherapy drug is u1 (t) and M denotes the decrease
in tumor cells due to the chemotherapy agent. The assumption made is that the net
change in the tumor cell population is the difference between the increase in cells due to
cell proliferation, and decrease in cells due to the chemotherapy drug injection M(·). The
chemotherapy drug used in equation (1.6 is assumed to be nonspecific phase Alkylating
agents so that, differences in growth fraction are insignificant thus, the proportion of cells
killed depends on the tumor growth rate.

The drug effect term is usually considered

proportional to the tumor cell population, so M(x, u1 ) = σx1 u1 .

According to [35],

the Pharmacokinetics is not taken into account, because the drug dosage is equal to the
concentration of the chemotherapy drug in the body however, that is an inaccurate depiction.
The authors suggest evaluating the concentration by adding another state x3 to represent
the chemotherapeutic concentration:

x˙3 = −ax3 + bu1 , x3 (0) = 0.
Equation (1.7) allows us to model the drug concentration growth or decay.

(1.7)
The

chemotherapy also has an effect on the lymphocyte cells. The authors in [41] proposed
a model that takes account the effects of chemotherapy agents on the lymphocyte cells:

8

x˙2 = µI J (x1 , x2 ) − L(x2 , u1 )−, x2 (0) = x02 .

(1.8)

where L(x2 , u1 ) is the effect of chemotherapy agent on lymphocyte cells. It will have an
adverse effect on both the tumor and lymphocyte cell populations.

1.2.4

Modeling Immunotherapy

In section 1.2.4, we summarize facts about immunotherapy from [2] and introduce the notion
of modeling immunotherapy on the tumor-immune interaction dynamic. The immune system
instinctively combats infections and diseases. It is made up of white blood cells, organs, and
lymph tissues. One of the tasks of the immune system, is to detect and destroy abnormal
cells and prevents the growth of cancer tumors. Ordinarily immune cells can be found in and
around tumors. These cells referred to as tumor-infiltrating lymphocytes or TILs are a
sign that the immune system is responding to the tumor. It has been found that patients
whose tumors have TILs often have a better chance in fighting cancer.
Although the immune system can halt or minimize cancer growth, cancer cells have ways
to evade the immune system. Cancer cell’s defence mechanism includes:
• Changing their genetic structures to imperceptible to the immune cells.
• They have proteins on their surface of that can disengage immune cells.
• Interfering with the response of the immune cells by changing the formation of the cells
on the surface of the tumor.
It is evident that in some cases the immune system is successful in combating the tumor
however, if the tumor growth expands, immunotherapy can help the immune system fight
cancer. There are various types of immunotherapies used to treat cancer, these include [2]:
• Immune checkpoint inhibitors, They block proteins that are called immune
checkpoints. These checkpoints keep the immune response from being too strong.

9

When the check points are blocked they allows immune cells to be more severe and kill
cancer cells.
• T-cell transfer therapy, The most active T-cells (immune cells) in a patient’s body
combating against the tumor are extracted. In the lab they reproduce and modify those
T-cells to better kill the cancer cells. Then they are injected back into the patient’s
blood stream.
• Monoclonal antibodies, which are immune proteins created in the lab to mark the
cancer cells so that the immune system can easily spot and target the cancer cells.
• Treatment vaccines, which are used to boost the immune system. They are different
from normal vaccines that prevent viruses or disease.
Immunotherapy is not as widely used as other therapies such as chemotherapy, radiation, and
surgery. In addition, not all patients respond to immunotherapy. There’s ongoing clinical
research to find better combinations of immunotherapies to treat cancer.
Constructing a mathematical model to capture the mechanism of the immunotherapy is very
complex and there are unknown parts of the system. According to [21], although there have
been large strides in biological modeling, there are still some open questions in immune
system modeling. The dynamic of the innate and immune response need to be examined at
the molecular tissue and cellular level to better grasp the dynamics of the immune system.
Researchers have focused on the immune system parts that have significant effect on tumor
growth [17]. A general model that is accepted among oncology researchers presented in [19]
formulates the tumor-immune interaction as follows:

x˙1 = µC x1 (1 −

x1
) − γx1 x2 − σx1 u1 ,
x∞

x˙2 = µI x1 x2 − µI βx21 x2 − χx2 + α + λx2 u2 .

(1.9)

We will use the model represented by the system in (1.9) in the thesis with a modification
introduced in equation (1.7).
10

1.3

Background and Overview

The dynamic tumor growth model in [40] is used in this thesis. The model is concerned
with tumor-immune interaction with the presence of outside control to achieve the necessary
outcome. Two control methods are used to attain a healthy state: Model Free Control (MFC)
and Optimal Control (OC). OC introduces an objective function which is the goal that the
control tries to reach, while the MFC technique steers the controls toward the healthy state
and injects it back into the dynamical model in iterative fashion. In the following subsections
we provide a brief introduction of the control techniques used.

1.3.1

Optimal Control

Optimal Control theory is a mathematical optimization method that obtains a control to
produce the best outcome possible based on a predetermined goal. It is also referred to
as dynamic optimization [36]. Optimal Control strategies have long been used in dynamic
models. In [22], optimal control was used for harvesting in a predator-prey parabolic system,
while in [16] it was used for maximizing final yield when growth is limited by time or
resources. For more examples of optimal control strategies see [13, 15, 18, 17].
In this research, the OC method is used to control the dynamical tumor model for a specified
time interval. We use varying objective functions and impose different constraints on the
states and control inputs. We analyze the different OC objective functions to capture the
optimum solution. In the case of the tumor growth model the desired outcome is to treat
the virtual patient and reach a healthy equilibrium using minimal chemotherapy injections.
Although chemotherapy has shown successful outcome in treating cancer, it can causes
serious side effects, and high dosages can be toxic.

1.3.2

Model Free Control

Through research and derivation of mathematical equations different control methods have
been developed. The formulation of control methods differ, but the ultimate objective is to
control the system. Model Free Control is an intelligent Proportional Integration Derivative
controller (iPID), which uses an online approach to estimate parameters [24]. Although
11

MFC was only introduced in 2008-2009 [23] it was applied to numerous control problems
in different areas and displayed favorable results. For example implementing MFC to study
immune response in [13], MFC was also used for controlling intelligent transportation systems
in [9]. For more examples on MFC applications see [14, 11, 45].
Using functional analysis and elementary differential algebra, MFC can be applied to
complex models to deduce control inputs capable of acquiring desirable outcomes. The
MFC methodology includes a set of parameters that need to be tuned by trial and error,
and are dependent on the dynamics of model. A detailed interpretation of the theoretical
formulation of MFC control will be presented later in chapter ??.

1.4

Summary of Contributions

The contribution of the thesis is summarized as follows:
1. The thesis proves the nonlinear cancer model is locally controllable. The controllability
matrix is found and the rank is calculated. It is important to establish that the system
is indeed controllable in order to reach the goal of treating the patient. If the system
is uncontrollable then the therapies used are deemed insufficient and will not help the
patient get to a healthy state.
2. The thesis proves the nonlinear cancer model is locally observable. The observability
matrix is found and the rank is calculated. It is important to establish that the system
is indeed observable in order to have a clear understanding of the behavior of the
dynamic cancer model.
3. Using OC methods, the cancer patient is cured and recovers within a 60-day treatment
regimen.

The OC strategy proves to be successful when tested under different

constraints and initial conditions.
4. The model-free control method was also explored. The online intelligent controller
showed positive results and was able to provide a successful treatment regimen within
the 60-day treatment period. Some of the MFC parameters displayed better results
and so they were selected by means of trial and error.
12

1.5

Organization of Thesis

The Thesis is organized as follows:– Chapter 2 introduces the dynamical model of the tumor-immune interaction. The
parameters of the model will be defined. Based on the dynamical model the
healthy equilibrium and unhealthy equilibrium are derived.
– In Chapter 3 the concept of controllability and observabilty for the nonlinear
dynamical model consisting of ODE is explained.

The Controllability and

Observability rank is calculated.
– Chapter 4 gives an in-depth examination of two distinct control methods: OC and
MFC. The control methods are applied to the virtual patient to derive suitable
controls to treat the patient and the results are presented.
– Chapter 5 concludes the work that has been done in this research thesis and
suggests future work to be explored.
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Chapter 2
The Cancer Mathematical Model
tumor-immune biological models were first introduced in 1980 by Stepenova [44]. In Chapter
2 we introduce the mathematical cancer model for the tumor-immune interaction. The
model explored throughout the thesis was previously introduced in [40]. The author in [35],
deduced that the dosage of the therapy is not equal to the amount of drug concentrated in
the patient’s body, so the initial model used in [19] and [39] has been expanded by adding
a state representing pharmacokinetics (PK) which captures the amount of chemotherapy
concentrated in the patient’s body.

2.1

Virtual Patient

The mathematical model is composed of nonlinear ODEs, which represents the tumorimmune interaction given by equations (2.1) - (2.3).
x˙1 = µC x1 −

µC 2
x − γx1 x2 − σx1 x3 ,
x∞ 1

(2.1)

x˙2 = µI x1 x2 − µI βx21 x2 − χx2 + α + λx2 u2 − %x3 x2 ,

(2.2)

x˙3 = −ax3 + bu1 .

(2.3)

The biological model referenced above is attentive to the progression of Tumor Cells
(TC) population, the Lymphocyte Cells (LC) population, and the chemotherapy drug
concentration. A tumor can either be malignant (cancerous) or benign (non-cancerous). The
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tumor forms as a result of abnormal cells dividing in the body. The cells in the human body
continuously divide for repair and growth. However, the tumor formation is an irregularity
that can lead to cancer. The TC count is observed by equation (2.1).
LCs are a type of white blood cells composed mainly of B lymphocytes and T lymphocytes.
B lymphocytes make antibodies, while T lymphocytes help kill tumor cells and help control
immune responses [3]. LC count can be an indication of the body’s immune response. LC
count is observed by equation (2.2).
Monitoring levels of chemotherapy concentration in the body is extremely important in
cancer treatment. Using high quantities of chemotherapy can be toxic and lead to death.
As mentioned previously, the concentration of chemotherapy existent in the body of the
patient is not equal to the chemotherapy dosage. The model monitors the chemotherapy
concentration in equation (2.3).
The dynamic cancer model is represented by the tumor-immune system interactions in the
presence of input variables: cytotoxic agents and immuno-stimulator to treat the virtual
patient. The aim is to move the initial conditions of the states from the malignant to the
benign region.
The tumor-immune system interaction is composed of three states:
• x1 : Tumor cell population;
• x2 : Lymphocyte cell population; and
• x3 : Chemotherapy drug concentration in patient.
The model comprises two time varying control inputs denoted as follows:
• u1 (t) : dosage of a cytotoxic agent; and
• u2 (t) : cytokines which is a generic immuno-stimulator.
The treatment duration of the model examined is 60-days. Given initial conditions of
the states and after performing the distinct control techniques, the condition of the virtual
patient is examined and the following outcomes can be expected:
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1. benign outcome: The treatment is considered successful in reducing the tumor size to
the benign equilibrium and preventing further spread of the cancer.
2. Malignant outcome: The treatment has failed in containing the spread of the cancer
leading the states to travel to the malignant equilibrium due to tumor growth and
immunity suppression.
When the dynamic model is uncontrolled: meaning that the time varying control inputs
are not injected in the system (u1 ,u2 =0) the outcome of differing initial conditions is given
in the phase portrait in figure 2.1. The phase portrait is the state space trajectory of the
system. It reveals invaluable information of the behavior of the system and determines
the equilibrium points. It can be seen from the phase portrait that the behavior of the
dynamic relies heavily on the initial conditions which is logical. It has been established that
the results of combating cancer in early stages is far more optimistic than the late-stage of
cancer when the spread has overwhelmingly reached lymph nodes and other parts of the
body. The macroscopic malignant equilibrium point is xm = (766.4, .018, 0), and the benign
one is xb = (41.45, .954, 0).
Although the state of the virtual patient can only be benign or malignant, the interplay of
interaction is not confined to tumor suppression or tumor expansion. On the contrary, studies
have shown that tumors may survive in microscopic levels having a dormant state, and can
be reactivated due to sudden events affecting the immune system [32]. If the immune system
experiences impairments due to disease or in some cases drugs such as immuno-suppressing
agents that are used to prohibit the immune system from causing damage to the body
preceding an organ transplant, then the tumor may restart developing [19].
Figure 2.2 illustrates the interconnections of the mathematical model in equations (2.1) (2.3) of tumor and immune interaction in the presence of other parameters and time varying
inputs. The larger shapes symbolize the states of the system which are the TCs, LCs, and
PKs. The two smaller shapes symbolize the time varying inputs consisting of chemotherapy
drug and immunotherapy stimulators. The lines connecting the states and inputs are the
parameters of the system which will be defined in table 2.1.
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The dynamic equations describe the interactions of the three states: x1 ,x2 , and x3 are
governed by various parameters and two time varying control inputs: u1 (t) and u2 (t). The
reference set of parameters are given in [40], and shown in Table 2.1 along with their
definitions and numerical values.
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Figure 2.1: Phase portrait of tumor-immune interaction model
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Figure 2.2: Diagram of tumor-immune system interaction in response to time varying input
controls consisting of u1 and u2 which denote chemotherapy and immunotherapy respectively
[40].

Table 2.1: Numerical values and definitions of the parameters in the cancer model [40].
Parameter
µC
µI
α
β
γ
χ
σ
λ
x∞
%
a
b
drug

Definition
tumor growth rate
tumor stimulated proliferation rate
rate of immune cells influx
inverse threshold
interaction rate
death rate
chemotherapeutic killing parameter
immunotherapy injection parameter
fixed carrying capacity
chemo-induced loss of immune cells
chemotherapy concentration decay
rate effect on chemotherapy concentration
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Numerical Value
1.0078 · 107 cells/day
.0029 day −1
.0827 day −1
.0040
1 · 107 cells/day
.1873 day −1
1 · 107 cells/day
1 · 107 cells/day
780 · 106 cells
1
0.5
1

Chapter 3
Nonlinear Controllability and
Observability
3.1

Introduction

Before designing a controller for any system, a control engineer must examine a system
and determine that it is controllable: the inputs injected into the system will achieve the
desired outputs. Systems deemed to be uncontrollable will behave at random and may never
achieve the required outputs. Controllability relates to our model in the sense that; the
chemotherapy and immunotherapy injections will indeed reduce the tumor size to the benign
region without compromising the health of lymphocyte cell count. Observability is also
another important concept which conveys how well the state variables are estimated based
on the output or the external states. In linear systems the controllability and observability
are easily checked based on the rank of the controllability and observability matrices, the
system can be verified as being controllable and or observable. However, the dynamic of the
tumor-immune interaction model is nonlinear and requires more rigorous computation. The
local controllability and local observability of the system can be checked using linear algebraic
manipulation of the system equations. Chapter 3 presents the concept of local controllability
and local observability of nonlinear systems alongside the computation to ascertain that
the system is locally controllable and locally observable. The theorems, definitions, and
equations used in chapter 3 are summarized from the work presented in [29, 27, 26, 30, 25].
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3.2

Nonlinear Controllability

The dynamical system is said to be locally controllable if there exists an external input u
that is able to move the internal state of a system from any initial state x0 to any other
final state x1 in a finite time interval. Otherwise, the system is said to be uncontrollable.
Note that controllability does not mean that the final state can be maintained, merely that
any state can be reached. Lie Brackets are used in calculating controllability matrix rank in
nonlinear system. The Lie Bracket and nonlinear controllability is defined below.
Definition 3.1. Consider two vector fields f (x) and g(x) in <n space. Then the Lie bracket
operation generates a new vector field [25]:

[f, g] ≡

df
dg
f−
g
dx
dx

(3.1)

Higher order Lie brackets can be defined as follows:
(ad1f ) ≡ [f, g],
(ad2f ) ≡ [f, [f, g]],
...
(adkf ) ≡ [f, (adk−1
f )]

f or k = [1, 2, ...].

(3.2)

Note: the ”ad” stands for adjoint.
Consider an affine control system

P

, described in local coordinates by [29]:


P

X ẋ(t) = f (x(t), u(t)) = f (x(t)) + m
i=1 gi (x(t))ui (t),
:

y(t) = h(x(t)),
x(0) = x0 .

(3.3)

where t 7→ ui (t) is a control function with values in a convex set Ω ⊂ IR, t 7→ x(t) is the
state trajectory with x(t) ∈ IRn , and t 7→ y(t) is the output curve with y(t) ∈ IRp . Given
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the system in equation (3.3) initialized at x0 , the map:
Sx0 : {t 7→ u(t), t ∈ [0, T ]} −→ {t 7→ y(t), t ∈ [0, T ]}

(3.4)

is called the input-output map.
and an initial state x0 . Let x1 be another state. Is it
P
possible to choose a control input t 7→ u(t) to steer
from x0 to x1 ? Is x1 accessible from
P
x0 ?
is said to be controllable if every state is accessible from every other state [29].
Suppose we are given a system

P

Theorem 3.2. The system is said to be locally accessible about a point x0 if and only if
the controllability matrix C spans IRn : rank (C)=n and C is defined by [25]:
C = [g1 , ..., gm , [f, g1 ], ..., [f, gm ], [f, (ad1f )], ..., [f, (adkf )]]

3.2.1

(3.5)

The Controllability Rank

In this section, the concept of nonlinear controllability is applied to the tumor-immune
interaction model to calculate the controllability matrix C defined in equation (1). The
tumor-immune interaction model given by equations (2.1) - (2.3) can be rewritten as:


X ẋ(t) = f (x(t)) + g1 (x)u1 + g2 (x)u2 ,
:

y(t) = h(x(t)), x(0) = x0 .

(3.6)

where f (x) is a function such that: IR3 → IR3 , x(t) ∈ IR3 , y: IR3 → IR2 . g1 (x),g2 (x), and
f (x) of system (3.6) are defined as follows:
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h
iT
g1 = 0 0 b ,
h
iT
g2 = 0 λx2 0 ,


C
x21 − γx1 x2 − σx1 x3
µC x1 − xµ∞




f (x) = µI x1 x2 − µI βx21 x2 − χx2 + α − %x3 x2  .


−ax3

(3.7)
(3.8)

(3.9)

From theorem 3.2 and the defined functions of the dynamical system in (3.7)-(3.9) the
controllability matrix becomes:

h
i
C = g1 , g2 , [f, g1 ], [f, g2 ], [f, [f, g1 ]], [f, [f, g2 ]] .

(3.10)

The controllability matrix is calculated using the Matlab function ”liebracket” which
results in:


0 0
3
x1 x1 x2 .. ..




C = 0 x2 const x2 .08 .. ..


1 0
3
1/2
0
.. ..

(3.11)

The rank of C = 3 which means the system is deemed locally controllable. Note that
columns five and six of C are not calculated because the current matrix C has a rank of
three and cannot go any higher, so there is no need for further calculations.
P
System
defined in equation (3.6) is locally controllable; which means that every state
is accessible from every other state. In other words, the virtual patient can be treated by
using chemo and immunotherapy u1 and u2 , respectively, to compress the TC (x1 ) while
maintaining a healthy level of lymphocytes (x2 ) in the patient’s body.
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3.3

Nonlinear Observability

Intuitively, a system is said to be observable if in a finite system the previous states can
be obtained by observing sensor measurements. For controllability in nonlinear systems
the concept of accessibility is studied, similarly for observability in nonlinear systems it is
expressed by the notion of distinguishability.

Definition 3.3. Two states x0 and x1 are distinguishable if there exists an input function
u∗ (t) such that: f (x0 ) 6= f (x1 ) [25].
To obtain the local observability matrix the ”Lie derivative” is used.
Definition 3.4. Given a system ẋ = Ax [25],
zi = Mi x

i ∈ [1,p],

Mi is 1×n vector

=⇒ zi = hi (x) = L0f (hi )
z˙i = L1f (hi )
(k)



L0f (h1 )

L0f (hp )

= Lkf (hi )

M1 x


=
...

M1 An−1 x
Lie derivative

z
i



...
...
Mp x






Define G =  ...

...
... 
...
...



n−1
n−1
Ln−1
(h
)
...
L
...
M
A
x
(h
)
1
p
p
f
f
0
Note that the term Lf (h) = h and the
looks like :


f (x)

h
i 1


dh
dh
Lf (h) = dx , ..., dx  ...
 =⇒ Lf (h) is a scalar.
1
2


fn (x)
Now, a gradient operator is defined:


dL0f (h1 ) ... dL0f (hp )




dG = 
=O
...
...
...


n−1
n−1
dLf (h1 ) ... dLf (hp )
O is the local observability matrix.
For control u∗ , and initial state x0 , the local observability matrix is defined as follows:
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dL0f (h1 )









...




0
 dLf (hp ) 
0
∗


O(x , u ) = 

n−1
dLf (h1 )






...


n−1
dLf (hp )

(3.12)

Theorem 3.5. Let G denote the set of all finite linear combinations of the Lie derivative of
h1 ,...,hp with respect to f for various values of u(t) (constant value). Let dG denote the set
of all their gradients. If n linearly independent vectors are found within dG, then the system
is locally observable [25].
The system is locally observable, that is distinguishable at point x0 if there exists a
neighborhood of x0 such that in this neighborhood,
x0 6= x1 =⇒ z(x0 ) 6= z(x1 )
”if the sensor reading are different, then the states are different”

3.3.1

The Observability Rank

Applying the definitions and theorems of section 3.3; the local observability matrix of the
tumor-immune interaction model is defined as follows:



dh1







 dh2 




 dh3 

O=
 1

dLf (h1 )


 1

dLf (h2 )


1
dLf (h3 )
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(3.13)

where h1 , h2 , h3 are equal to x1 , x2 , and x3 , respectively, and L1f (h1 ), L1f (h2 ) and L1f (h3 )
are equal to f1 , f2 and f3 , respectively. It is easily determined that the observability matrix
dh1 , dh2 , and dh3 forms a 3x3 identity matrix which will have a rank of 3. This means that
the system is locally observable.

3.4

Controllability and Observability Summary

Controllability addresses the issue of actuation and the ability of the actuators to control
the states of the system. On the other hand, observability addresses the issue of sensing and
the ability of the sensors to capture the dynamical behavior of the system.
Observability is the dual notion of controllability. It deals with determining the states of the
system from the knowledge of the input u(t) and output y(t). More precisely:
1. Observability refers to determining the initial state x0 from future inputs and outputs
u(t) and y(t), respectively, for duration time T .
2. Controllability refers to determining the final state x1 from past inputs and outputs
u(t) and y(t), respectively, for duration time T .
From the theorems and definitions referenced in chapter 3, it was determined that the system
is locally controllable and locally observable.
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Chapter 4
Applying Distinct Control Techniques
on tumor-immune Interaction Model
4.1

Control of Nonlinear Systems

Nonlinear control theory is concerned with nonlinear analysis of dynamic systems. The
systems can be Time Invariant (TI) or Time Varying (TV). In TI systems the dynamical
model is not time dependant while a TV system is. The tumor-immune model does not
depend on time so it is considered to be TI. Nonlinear systems do not adhere to the
superposition principle. Nonlinear control deals with applying mathematical techniques for
stability analysis and designing nonlinear feedback control [30, 28]. Chapter 4 will cover
the use of two different control techniques: optimal control and model free control. After
formulating the control techniques to design a controller to drive the tumor to the safe region,
we run simulations and preview results.

4.2

Optimal Control

Optimal Control theory is concerned with finding an adequate control input for a system,
such that the optimality criterion is achieved. The optimal control problem has an objective
function composed of state and input variables. For e.g. a sufficient objective function in the
cancer immune system would be to minimize the tumor size. An objective function is chosen
27

by the practitioner to achieve a certain objective. What follows was summarized from the
work presented in [36, 39]. In section 4.2, we introduce the mathematical definitions and
formulation of the OC.
Definition 4.1. Consider a system with n state variables, m control inputs, and a payoff
function Γ [36],
Z

t1

J = inf

f (t, x1 (t), ..., xn (t), u1 (t), ..., um (t))dt + Γ(x1 (t1 ), ..., xn (t1 ))

u1 ,...,um

t0

subject to
ẋi (t) = gi (t, x1 (t), ..., xn (t), u1 (t), ..., um (t)),
xi (t0 ) = xi0 f or i = 1, 2, ..., n,

(4.1)

where f and gi are continuously differentiable in all variables. There are no requirements on
m,n. The system at hand has three states and two inputs (m = 2, n = 3). where x ∈ IRn is
the state, u ∈ IRm is the control input, functions f : IR × IRn × IRm 7→ IR, g : IR × IRn ×
IRm 7→ IR, and Γ: IRn 7→ IR are polynomials.
Remark 1. The Objective function also known as the cost function ”J” is selected based on
the desired goal. It can have numerous terms, such as setting the end bounds for the final
states or integrals of inputs to satisfy different control objectives.
Formulating the nominal Optimal Control problem using definition 4.1 yields
Z
J = min
u1 ,u2

60

f (t, x1 , x2 , x3 , u1 , u2 )dt
0

subject to
x˙1 = µC x1 −

µC 2
x − γx1 x2 − σx1 x3 ,
x∞ 1

x˙2 = µI x1 x2 − µI βx21 x2 − χx2 + α + λx2 u2 − %x3 x2 ,
x˙3 = −ax3 + bu1 .
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x(0) = xt0 = {500, 0.5, 0},
x(60) = xt1 = {41.45, 0.954, 0},
0 ≤ u1 ≤ 1, 0 ≤ u2 ≤ 1,
0 ≤ x1 ≤ 780,
0 ≤ x2 ≤ 5,
t ∈ [0, 60].

(4.2)

Remark 2. The states have fixed end points defined by xt1 which ensures that the states will
reach the benign region by the end of the time interval at t1 = 60.
Remark 3. The control inputs u1 and u2 are bounded between [0,1] in the normalized system
dynamic where the maximum dosage injection is 1.
Remark 4. Constraints are added to the states to ensure practical limits and compactness
of the state set.
Remark 5. The different objective functions used are as follows:
f1 = (x1 + x2 ) dt,

(4.3)

f2 = (x21 + x22 ) dt, and

(4.4)

f3 = (u21 + u22 ) dt.

(4.5)

Optimal Control allows formulation of control problems as mathematical optimization
problems. OpenOCL provides a modeling language that helps to implement a direct
collocations method, and interfaces CasADi and ipopt to solve nonlinear system dynamics
[33, 12]. The toolboxes are used in conjunction with Matlab to solve the optimal control
problem and simulates the state trajectories after solving for the optimal inputs u∗1 and u∗2 .
Note that the objective function must be formulated in a manner to achieve the objective.
In the tumor-immune interaction model, we minimize the controls to drive the state to the
benign region. The reason for minimizing the chemotherapy and immunotherapy injections
is due to their toxicity. Over dosage of the injections is life threatening and may lead to a
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death outcome. For example overusing the cytotoxic agent u1 may rid the patient of the
tumor cells but also lead to death; although the tumor was treated the patient is dead which
defeats the purpose of the treatment. In the addition, the immunotherapy injection u2 is also
toxic if used in large amounts and so it must be constrained accordingly. The constraints of
the optimal control problem in equation (4.2) will keep the system in the safe region, thus
the treatment is safe and the patient will not be subject to poisoning due to overdose of the
chemical agents used for treatment.

4.2.1

Simulations

In section 4.2.1 the OC method is applied to the cancer dynamical model and the system (4.2)
was used to formulate the OC problem and the results from the simulations are presented.
As can be seen the OC method successfully treated the virtual patient within the treatment
duration, but only after choosing the correct objective function given by equation (4.5). The
OC method converged to the benign equilibrium in approximately forty days in most cases.
The OC technique also reserved the use of chemotherapeutic agent; large doses were used
in cases with an initially high tumor cell count and only for approximately the first 10-days
of the treatment regimen. The results are presented in figures 4.1 - 4.7. Equations (4.3),
(4.4), and (4.5) were used to produce the state trajectories in figures 4.1, 4.2, and 4.3 - 4.7,
respectively.

4.3

Model Free Control

The MFC technique and procedure in section 4.3 was summarized from the work presented
in [13, 23, 24]. Model Free Control is based on a continuously updated local model using
the knowledge of the input-output behavior of the system. The framework behind MFC was
derived using differential algebra. The advantage of using MFC, is that unknown or finite
dimensional complex models can be replaced with an ultra local model [24]. It is an online
controller because it continuously examines the current and previous states of the system to
derive the inputs for the next iteration. MFC is applied to the cancer model and the results
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Figure 4.1: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). Initial condition is x0 = (500, 0.5) and the integrand
in the cost function is f = x1 + x2 .
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Figure 4.2: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). Initial condition is x0 = (500, 0.5) and the integrand
in the cost function is f = x21 + x22 .
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Figure 4.3: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). Initial condition is x0 = (30, 0.2) and the integrand in
the cost function is f = u21 + u22 .
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Figure 4.4: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). Initial condition is x0 = (100, 0.2) and the integrand
in the cost function is f = u21 + u22 .
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Figure 4.5: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (330, 0.9) and the integrand
in the cost function is f = u21 + u22 .
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Figure 4.6: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (500, 0.5) and the integrand
in the cost function is f = u21 + u22 .
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Figure 4.7: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). Initial condition is x0 = (700, 0.7) and the integrand
in the cost function is f = u21 + u22 .
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are presented. The next set of equations define the methodology behind model free control
[23].

y (v) = Fest + αu
Z t−L
−6
Fest = 3
(L − 2σ)y(σ) + ασ(L − σ)u(σ)dσ
L
t
e = y − y∗
u=

(4.6)
(4.7)
(4.8)

Fest − y˙∗ + Kp e
α

(4.9)

where
• y (v) is the derivative of order v >= 1 of y.
• u and y are the control input and output variables.
• Fest represents the plant estimate in its entirety including the poorly known parts, and
the disturbances.
• α is a constant parameter that is selected such that y (v) and αu are of the same
magnitude.
• y ∗ is the reference trajectory.
• e is the tracking error.
Implementing the MFC procedure is done in the following order [13]:
1. Set u1 = 0, define reference trajectory y1∗ , and initialize Kp1 and α1
2. Obtain measurement of states x1 and inputs u1
3. Estimate Fest1 by using equation (4.7)
4. calculate u1 according to equation (4.9) and return to step 2.
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Remark 6. Since the cancer model used contains two inputs and three outputs we will treat
them as a decoupled system and find u1 and u2 accordingly.
Remark 7. To avoid any confusion α is a parameter in the cancer model, while α1,2 is a
parameter used in the Model Free Control method.
The MFC parameters are shown in table 4.1.
• Selecting α1,2 is done through trial and error to obtain desired results of the output
states x1 ,x2 . The states will vary widely depending on the numerical values chosen
for α1,2 . This shows that MFC parameters chosen are specific to the model they are
intended for. As stated in [24] α1,2 is not a priori defined parameter, but it is chosen
by the practitioner.
• L represents the number of the most recent measurements considered for each iteration
of the MFC.
∗
• y1,2
is the reference trajectory which is the benign equilibrium which is where we want

the states x1 , x2 to settle.
• The sample time tsamp1,2 is .1 so for 60 days there is 601 samples.
• Kp1,2 represents the tuning parameters for MFC. In the same fashion of finding α1,2 ,
the tuning parameters are determined by trial and error.

4.3.1

MFC Simulations

In section 4.3.1 the MFC method is applied to the cancer dynamical model using parameters
in table 4.1 and the results from the simulations are shown. As can be seen, the MFC method
successfully treated the virtual patient by reducing the tumor size through chemotherapy
and immunotherapy injections over the period of the treatment while maintaining safe levels
of Lymphocyte cell population. It is evident from the figures 4.8 - 4.17 that the model free
control method converges within approximately twenty days, half the time it takes when
using the optimal control method. However, the MFC method uses the chemotherapeutic
agent u1 immoderately even in cases where there is a low number of tumor cells in the initial
condition.
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Figure 4.8: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (500, 0.5).
Table 4.1: Numerical values and definitions of the Model Free Control parameters
MFC Parameter
Definition
Numerical Value
α1,2
magnitude adjuster
1000, 5000
L1,2
past measurements taken
3, 3
∗
y1,2
Reference Trajectories
41.45, 0.954
tsamp1,2
time lapse
0.1, 0.1
Kp1,2
Tuning parameters
0.001, 6
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Figure 4.9: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (700, 0.7).
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Figure 4.10: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (30, 0.2).
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Figure 4.11: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (100, 0.2).
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Figure 4.12: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (330, 0.9).
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Figure 4.13: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (250, 1.2).
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Figure 4.14: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (350, 1.2).
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Figure 4.15: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (80, 0.5).

47

Figure 4.16: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The initial condition is x0 = (100, 0.5).

48

Figure 4.17: Plot of tumor and immune cells x1 and x2 , respectively, in response to time
varying input controls (u1 ) and (u2 ). The Initial condition is x0 = (200, 0.7).
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Chapter 5
Conclusion and Future Works
In this thesis, we introduced a dynamical model of tumor-immune interaction of a virtual
patient. The benign and malignant equilibrium points were calculated to see how the
dynamic model will react for different initial conditions with absent controls; chemotherapy
and immunotherapy injections. We successfully showed that the mathematical model was
locally controllable and observable. Hence, we implemented two distinct control techniques
to treat the virtual patient and reduce the tumor size to the benign region. Optimal control
and model free control were successful in curing the patient within the treatment period and
the results were presented. To obtain the desired results we needed to define the correct
objective functions of the OC problem and solve it given the constraints of the system. On
the other hand, some of the MFC parameters needed some tuning through trial and error to
produce the sought after results. We observed that using the OC resulted in driving the states
to the benign region in approximately forty days and the use of chemotherapeutic agents
was minimized, especially for low initial tumor cell populations. The MFC consistently
used chemotherapy even when the initial condition of the tumor cells was relatively low.
This presents a trade-off between treatment time and the use of chemotherapy. It would
be interesting to apply the control techniques in a real setting, where the data is measured
and the cancer model is simulated to obtain the optimal control injection dosages to treat a
patient.
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A

Summary of Equations

A brief recap of the equations and formulas used throughout the thesis is summarized below.

A.1

Tumor Immune Interaction Model

The mathematical model of nonlinear ODE representing the tumor-immune interaction is
given below:
x˙1 = µC x1 −

µC 2
x − γx1 x2 − σx1 x3 ,
x∞ 1

x˙2 = µI x1 x2 − µI βx21 x2 − χx2 + α + λx2 u2 − %x3 x2 ,
x˙3 = −ax3 + bu1 .
The tumor-immune system interaction is composed of three states [40]:
• x1 : Tumor cell population;
• x2 : Lymphocyte cell population; and
• x3 : Chemotherapy drug concentration in patient.
The model comprises two time varying control inputs denoted as follows:
• u1 (t) : dosage of a cytotoxic agent; and
• u2 (t) : cytokines which is a generic immuno-stimulator.

A.2

Nonlinear Controllability

The system is said to be locally accessible about a point x0 if and only if the controllability
matrix C spans IRn : rank (C)=n and C is defined by [25]:
C = [g1 , ..., gm , [f, g1 ], ..., [f, gm ], [f, (ad1f )], ..., [f, (adkf )]]
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(1)

Consider two vector fields f (x) and g(x) in <n space. Then the Lie bracket operation
generates a new vector field [25]:

[f, g] ≡

dg
df
f−
g
dx
dx

(2)

Higher order Lie brackets can be defined as follows:
(ad1f ) ≡ [f, g],
(ad2f ) ≡ [f, [f, g]],
...
(adkf ) ≡ [f, (adk−1
f )]

f or k = [1, 2, ...].

Note: the ”ad” stands for adjoint.

A.3

Nonlinear Observability

For control u∗ , and initial state x0 , the local observability matrix is defined as follows:


dL0f (h1 )









...




0
 dLf (hp ) 
0
∗

O(x , u ) = 

 n−1
dLf (h1 )






...


dLn−1
(h
)
p
f
where dL is the Lie derivative.
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(3)

A.4

Nonlinear Optimal Control

Consider a system with n state variable, m control inputs, and a payoff function Γ,
Z

t1

J = inf
u1 ,...,um

f (t, x1 (t), ..., xn (t), u1 (t), ..., um (t))dt + Γ(x1 (t1 ), ..., xn (t1 ))
t0

subject to
ẋi (t) = gi (t, x1 (t), ..., xn (t), u1 (t), ..., um (t)),
xi (t0 ) = xi0 f or i = 1, 2, ..., n,

A.5

Model Free Control
y (v) = Fest + αu
Z t−L
−6
Fest = 3
(L − 2σ)y(σ) + ασ(L − σ)u(σ)dσ
L
t
e = y − y∗
u=

Fest − y˙∗ + Kp e
α

where
• y (v) is the derivative of order of v >= 1 of y.
• u and y are the control input and output variables.
• Fest represents the plant in it’s entirety including the poorly known parts, and the
disturbances.
• α is a constant parameter that is chosen such that y (v) and αu are of the same
magnitude.
• y ∗ is the reference trajectory.
• e is the tracking error.
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